BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25726713)

  • 21. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel hedgehog inhibitor for the treatment of hematological malignancies.
    Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
    Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Hedgehog Antagonists for Cancer Therapy.
    Khatra H; Bose C; Sinha S
    Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel therapeutic approach against B-cell non-Hodgkin's lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy.
    Fan J; Zeng X; Li Y; Wang S; Yang P; Cao Z; Wang Z; Song P; Mei X; Ju D
    Tumour Biol; 2016 Jun; 37(6):7305-14. PubMed ID: 26666826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer.
    Yun JI; Kim HR; Park H; Kim SK; Lee J
    Arch Pharm Res; 2012 Aug; 35(8):1317-33. PubMed ID: 22941475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics.
    Peukert S; Miller-Moslin K
    ChemMedChem; 2010 Apr; 5(4):500-12. PubMed ID: 20229564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway.
    Sekulic A; Mangold AR; Northfelt DW; LoRusso PM
    Curr Opin Oncol; 2013 May; 25(3):218-23. PubMed ID: 23493193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging drugs and combination strategies for basal cell carcinoma.
    Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hedgehog inhibition as an anti-cancer strategy.
    Raju GP; Pham D
    Vitam Horm; 2012; 88():507-22. PubMed ID: 22391319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition.
    Cohen DJ
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):565-88, viii. PubMed ID: 22520980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulators of the hedgehog signaling pathway.
    Heretsch P; Tzagkaroulaki L; Giannis A
    Bioorg Med Chem; 2010 Sep; 18(18):6613-24. PubMed ID: 20708941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies.
    Galperin I; Dempwolff L; Diederich WE; Lauth M
    J Med Chem; 2019 Sep; 62(18):8392-8411. PubMed ID: 30986059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
    Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
    Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.
    Xu FG; Ma QY; Wang Z
    Cancer Lett; 2009 Oct; 283(2):119-24. PubMed ID: 19232458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
    Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
    Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.